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Abstract
Pilot studies are often used to transition therapies developed using animal models to a clinical
setting. Frequently, the focus of such trials is on estimating the safety in terms of the occurrence
of certain adverse events. With relatively small sample sizes, the probability of observing even
relatively common events is low; however, inference on the true underlying event rate is still
necessary even when no events of interest are observed. The exact upper limit to the event rate
is derived and illustrated graphically. In addition, the simple algebraic expression for the confidence
bound is seen to be useful in the context of planning studies.
Introduction
In the translational research setting, statisticians often
assist in the planning and analysis of pilot studies. While
pilot studies may vary in the fundamental objectives,
many are designed to explore the safety profile of a drug
or a procedure [1,2]. Often before applying a new therapy
to large groups of patients, a small, non-comparative
study is used to estimate the safety profile of the therapy
using relatively few patients. This type of investigation is
typically encountered in the authors' experiences as col-
laborating biostatisticians at our General Clinical
Research Center as well as developing applications
addressing the National Institutes on Health Roadmap
Initiative http://nihroadmap.nih.gov/.
In the context of pilot studies, traditional levels of α (the
Type I error rate) and β (the Type II error rate) may be
inappropriate since the objective of the research is not to
provide definitive support for one treatment over another
[3]. For example, the null hypothesis in a single arm pilot
study might be that the tested intervention produces a
safety profile equal to a known standard therapy. A Type I
error (rejecting the null hypothesis when it is false) in the
context of this preliminary investigation would encourage
additional examination of the treatment in a new clinical
trial. This is in contrast to a Type I error in a Phase III/IV
clinical trial in which the error could result in widespread
exposure of an ineffective treatment. Allowing for a less
stringent Type I error rate is critical when trying to transi-
tion therapies from the animal models to clinical practice
since it identifies a greater pool of potential therapies that
could undergo additional research in humans.
Similarly, power (1 - β) is of less practical importance in a
single arm, non-comparative (or historically controlled)
pilot study since the results would almost always require
confirmation in a controlled trial setting. Shih et al [4]
extend the deviations from traditional hypothesis-driven
analyses to suggest preliminary investigations should
focus on observing responses at the subject level rather
than testing a treatment's estimated mean response. In the
section that follows, we will relate these notions under the
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context of safety data analysis and provide interpretations
that can be used for sample size considerations.
Methods
For ease of presentation, assume the pilot study will
involve n independent patients for which the probability
of the adverse event of interest is π, where 0 <π < 1. A 100
× (1 - α)% confidence interval is to be generated for π and
an estimate of the sample size, n, is desired. Denote X as
the number of patients sampled who experience the
adverse event of interest. Then, the probability of observ-
ing x events in n subjects follows the usual binomial dis-
tribution. Namely,
Denote πu as the upper limit of the exact one-sided 100 ×
(1 - α)% confidence interval for the unknown proportion,
π [5]. Then πu is the value such that
A special case of the binomial distribution occurs when
zero events of interest are observed. In pilot studies with
relatively few patients, this is of practical concern and war-
rants particular attention. When zero events are realized
(i.e., x = 0), equation (1) reduces to
(1 - πu)n = α.
Accordingly, the upper limit of a one-sided 100 × (1 - α)%
confidence interval for π is
πu = 1 - α1/n.   (2)
The resulting 100 × (1 - α)% one-sided confidence inter-
val is (0, 1 - α1/n).
Graphically, one can represent this interval on a plot of π
against n as illustrated in Figure 1 for α = 0.05, 0.10 and
0.25. As the figure illustrates, for relatively small sample
sizes, there is a large amount of uncertainty in the true
value of π. It is critical to convey this uncertainty in the
findings and to guard against inferring a potential treat-
ment is harmless when no adverse effects of interest are
observed with limited data. Louis [6] also cautioned the
clinical observation of zero false negatives in the context
of diagnostic testing stating that zero false negatives may
generate unreasonable optimism regarding the rate, par-
ticularly for smaller sample sizes.
Furthermore, one can consider using (2) in other clini-
cally important manners. For instance, an investigator
may be planning a pilot study and want to know how
large it would need to be to infer with 100 × (1 - α)% con-
fidence that the true rate did not exceed a pre-specified π,
say π0, given that zero adverse events were observed. Using
(2), it follows that:
To illustrate the utility of this solution, consider the fol-
lowing example. Ototoxicity is well documented with
increasing doses of cisplatin, a platinum-containing anti-
tumoral drug that is known to be effective against a variety
of solid tumors. It is of clinical interest to identify aug-
mentative therapies that can alleviate some of the cell
death since up to 31% of patients receiving initial doses of
50 mg/m2 cisplatin are expected to have irreversible hear-
ing loss [7,8]. Therefore, it is desirable to rule out poten-
tial treatments not consistent with this rate of hearing loss
before considering more conclusive testing. Using equa-
tion (3), we would conclude that the augmentative ther-
apy has a hearing loss rate less than 0.31, at the 90%
confidence level, if a total of 7 patients are recruited and
all 7 do not experience ototoxicity. Therefore, an initial
sample size of 7 patients would be sufficient to identify
augmentative therapies, such as heat shock or antioxidant
supplements, that demonstrate preliminary efficacy in
humans. In the event one or more ototoxic events are
observed, then the results in relationship to the historical
rate (31% in this example) may not be statistically
Upper limit of the 100 × (1 - α)% one-sided confidence inter- val for the true underlying adverse event rate, π, for increas- ing sample sizes when zero events of interests are observed Figure 1
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val for the true underlying adverse event rate, π, for increas-
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different. The results of several of these pilot studies could
then be used to rank-order potential therapies thereby
proving an empirically justified approach to therapy
development.
Conclusions
In translational research, it is common to explore the
adverse event profile of a new regimen. In this note, we
illustrate how a simple expression has utility for the gen-
eration of confidence intervals when zero events are
observed. A more comprehensive and methodological
treatment of inference with zero events can be found in
Carter and Woolson [9], and Winkler et al [10], which
treats the issue from a Bayesian statistical viewpoint. This
commentary and related works have implications as a
practical finding for the interpretation of clinical trial
safety data and offer clinicians advice on the range of
adverse event rates that can be thought to be consistent
with the observation of zero events. The presented for-
mula offers more flexibility than the "rule of 3" approxi-
mation [11] since it allows for the specification of
significance levels other than α  = 0.05. The ability to
choose the significance level might be important when
designing or interpreting preliminary data obtained from
a pilot study. In summary, small sample sizes and a focus
on safety are often associated with translational research,
and the statistical approaches to these studies may need to
deviate from traditional, hypothesis-driven designs.
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